KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
Fiche publication
Date publication
août 2016
Journal
The British journal of dermatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand
Tous les auteurs :
Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H, Bonnafous C, Dujardin A, Ram-Wolff C, Kadin ME, Bensussan A, Bagot M, Michel L
Lien Pubmed
Résumé
KIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sézary syndrome. Anti-KIR3DL2 targeted antibody therapy has shown potent activity in preclinical models for these diseases.
Mots clés
Adolescent, Adult, Aged, Antibodies, Monoclonal, pharmacology, Antineoplastic Agents, pharmacology, Cell Line, Tumor, Female, Humans, Ki-1 Antigen, metabolism, Killer Cells, Natural, physiology, Leukocytes, Mononuclear, metabolism, Lymphoma, Large-Cell, Anaplastic, drug therapy, Male, Middle Aged, Receptors, KIR2DL2, antagonists & inhibitors, Skin, metabolism, Skin Neoplasms, drug therapy, Tumor Cells, Cultured, Young Adult
Référence
Br J Dermatol. 2016 08;175(2):325-33